Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

KIDS vs SIBN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SIBN Captures Overall Composite Edge (49.6 HOLD vs 45.1 HOLD), While KIDS Leads 4–2 on Growth & Valuation Pillars

SIBN Overall Winner 6-Pillar Tally: KIDS 4 – 2 SIBN Matrix Metrics: KIDS 2 – 6 SIBN

As of Nov 19, 2026, SI-BONE, Inc. (SIBN) captures the overall head-to-head institutional edge over OrthoPediatrics Corp. (KIDS) on higher Unified Composite conviction (49.6/100 HOLD vs. 45.1/100 HOLD) after splitting the core matrix 6–2 (led by Profitability & Quality, Options & Positioning), while KIDS wins 4–2 across the 6-pillar growth and valuation breakdown. KIDS trades at $32.51 (N/M Forward P/E, -8.2% operating margin) versus SIBN at $23.75 (N/M Forward P/E, -7.6% operating margin).

  • Growth vs. Quality Trade-Off: SIBN earns the overall head-to-head edge with a stronger Unified Composite Score (49.6/100 HOLD vs. KIDS 45.1/100 HOLD) and 0.69β · 74% Vol risk profile, whereas KIDS leads top-line expansion (+18.6% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About KIDS vs SIBN
KIDS NASDAQ
OrthoPediatrics Corp. Common Stock
Surgical & Medical Instruments & Apparatus
$32.51
+2.72% 1D
Market Cap $850.2M
TTM Revenue $264M
Forward P/E N/M
Beta / 30D Vol 0.81β · 108% Vol
Unified Composite Score
45.1 / 100 HOLD
Tech 28.0 Fund 40.0 Flow 50.0 Mom 46.3
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (12.1% over 20 days), RSI 64
RSI-14: 64.2 · SMA20: $30.90 · SMA50: $25.86
SIBN NASDAQ Head-to-Head Winner
SI-BONE, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$23.75
+0.89% 1D
Market Cap $1.1B
TTM Revenue $221M
Forward P/E N/M
Beta / 30D Vol 0.69β · 74% Vol
Unified Composite Score
49.6 / 100 HOLD
Tech 34.0 Fund 51.0 Flow 72.0 Mom 56.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.7% over 20 days), RSI 58
RSI-14: 57.8 · SMA20: $23.21 · SMA50: $20.78

6-Pillar Scorecard Institutional Category Breakdown (KIDS 4 – 2 SIBN)

Columns: Metric · KIDS · SIBN
1. Valuation Multiples KIDS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 3.2x 4.8x
2. Growth & Scale KIDS
Revenue Growth (YoY) +18.6% +14.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $264M $221M
Market Cap $850.2M $1.1B
3. Profitability & Quality SIBN
Gross Margin 73.8% 79.4%
Operating Margin -8.2% -7.6%
Net Profit Margin -12.8% -6.2%
Return on Equity (ROE) -9.8% -7.7%
4. Balance Sheet & Cash Flow KIDS
Cash Generation (TTM) $1.1M EBITDA -$4.2M
Cash Flow Margin 0.4% EBITDA Mgn -1.9%
Net Cash / Leverage $12.99 Book/Sh · -9.8% ROE $7.5M Net Debt (0.23x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SIBN
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile 145.1% (100th %ile) 139.3% (45th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat KIDS
OpEx & R&D Intensity 82.0% of Rev ($217M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: KIDS (2) vs SIBN (6)
Institutional Metric KIDS SIBN Criterion Row Edge
Market Capitalization
Scale
$850.2M $1.1B Larger Scale SIBN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+18.6% +14.5% Higher Growth KIDS
Operating Margin (TTM)
Profitability
-8.2% -7.6% Higher Margin SIBN
Net Profit Margin
Profitability
-12.8% -6.2% Higher Margin SIBN
Return on Equity (ROE)
Capital Efficiency
-9.8% -7.7% Higher ROE SIBN
52-Week Range Position
Momentum
90% ($14–$35) 85% ($11–$26) Stronger Trend KIDS
Beta / 30D Volatility
Risk Regime
0.81β · 108% Vol 0.69β · 74% Vol Lower Realized Risk SIBN
Unified Institutional Score
Composite Signal
45.1 / 100 (HOLD) 49.6 / 100 (HOLD) Higher Composite SIBN
Trailing 12M Revenue (USD)
Operating Scale
$264M $221M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
73.8% 79.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.2x EV/Rev N/M PEG · 4.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.1M EBITDA ($12.99 Book/Sh · -9.8% ROE) -$4.2M ($7.5M Net Debt (0.23x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KIDS +22.3 pp
KIDS: +36.37% · SIBN: +14.07%
3M Horizon KIDS +7.75 pp
KIDS: +26.74% · SIBN: +18.99%
6M Horizon KIDS +16.04 pp
KIDS: +76.4% · SIBN: +60.36%
1Y Horizon KIDS +69.48 pp
KIDS: +98.84% · SIBN: +29.36%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KIDS vs SIBN. Trailing 12-month operating profitability (KIDS -8.2% vs SIBN -7.6%) and valuation multiples (KIDS N/M vs SIBN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

KIDS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$264M
Gross Margin73.8%
Op. Margin-8.2%
ROE / Fwd P/E-9.8% · N/M
SIBN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$221M
Gross Margin79.4%
Op. Margin-7.6%
ROE / Fwd P/E-7.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
KIDS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 145.1%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KIDS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SIBN BREAKOUT
77d in phase · OBV DISTRIBUTION
Current IV 139.3%
IV Percentile 45th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SIBN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
KIDS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $850.2M market capitalization and -8.2% operating margin.
OpEx & R&D Reinvestment 82.0% of Rev ($217M)
90D Engineering Disclosures 0 Published
SIBN Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.1B market capitalization and -7.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ KIDS vs SIBN Key Questions & Quantitative Answers

As of Nov 19, 2026, SI-BONE, Inc. (SIBN) captures the overall head-to-head institutional edge over OrthoPediatrics Corp. (KIDS) on higher Unified Composite conviction (49.6/100 HOLD vs. 45.1/100 HOLD) after splitting the core matrix 6–2 (led by Profitability & Quality, Options & Positioning), while KIDS wins 4–2 across the 6-pillar growth and valuation breakdown. KIDS trades at $32.51 (N/M Forward P/E, -8.2% operating margin) versus SIBN at $23.75 (N/M Forward P/E, -7.6% operating margin). Growth vs. Quality Trade-Off: SIBN earns the overall head-to-head edge with a stronger Unified Composite Score (49.6/100 HOLD vs. KIDS 45.1/100 HOLD) and 0.69β · 74% Vol risk profile, whereas KIDS leads top-line expansion (+18.6% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

KIDS leads the Growth & Scale pillar: KIDS posts +18.6% YoY revenue growth and +0.0% YoY earnings growth on $264M TTM revenue (73.8% gross margin, -8.2% operating margin), compared with SIBN at +14.5% YoY revenue growth and +0.0% YoY earnings growth on $221M TTM revenue (79.4% gross margin, -7.6% operating margin). On trailing 12-month operating scale, KIDS generates $264M in USD-normalized revenue versus $221M for SIBN. In operating R&D and SG&A reinvestment, KIDS deploys 82.0% of Rev ($217M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SIBN.

KIDS screens cheaper on headline valuation multiples. KIDS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.2x EV/Revenue (0.4% EBITDA margin), whereas SIBN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.8x EV/Revenue (-1.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KIDS (-9.8% ROE) versus SIBN (-7.7% ROE) capital efficiency.

In options market volatility and institutional positioning, KIDS carries 145.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.81β · 108% Vol realized risk). By comparison, SIBN carries 139.3% implied volatility (45th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKOUT options structure phase (0.69β · 74% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.